Indications
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Composition
- Active substance
- Glucagon
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ogluo
- Active substance
- Glucagon
- ATC code
- H04AA01
- Therapeutic area
- Diabetes Mellitus
- Marketing authorisation holder
- Strongbridge Dublin Limited
- Status
- Authorised
- EU authorisation
- 11 Feb 2021